THE EVOLUTION OF BIOACTIVE COSMETICS: NAVIGATING SCIENCE, SAFETY, AND CONSUMER EXPECTATIONS IN MODERN DERMATOLOGY

Nodar Sulashvili[1,2,3], Nana Gorgaslidze[1], Luiza Gabunia[1], Marika Sulashvili[1], Marina Giorgobiani[1], Irine Zarnadze[1], Shalva (Davit) Zarnadze[1]

[1]Tbilisi State Medical University, Georgia,
[2]International School of Medicine at Alte University, Georgia,
[3]Georgian National University SEU, Georgia,
[4]Tbilisi Humanitarian Teaching University, Georgia
n.sulashvili@ug.edu.ge

The cosmetics industry is rapidly transforming due to scientific innovation, rising consumer awareness, and the convergence of dermatology with aesthetics. The emergence of «cosmeceuticals» topical products bridging the gap between cosmetics and pharmaceuticals—has challenged outdated regulatory definitions and prompted a reexamination of skin health strategies. Originally intended for aesthetic enhancement, cosmetics have evolved into biologically interactive formulations. The U.S. Federal Food, Drug, and Cosmetic Act of 1938 defined cosmetics as products for beautification without affecting skin structure or function. However, modern formulations including anti-wrinkle creams, anti-inflammatory serums, and botanical antioxidants contradict this narrow definition. With advances in dermal imaging and molecular biology, it is now evident that even water, under certain conditions, can elicit inflammatory responses and alter keratinocyte activity. The widespread incorporation of herbs, vitamins, and marine extracts into skincare further challenges the classification of cosmetics as inert. Cosmeceuticals occupy a pivotal space between beauty and medicine. Their increasing biological activity challenges archaic legal frameworks and calls for science-driven, ethically sound product development. While advances in formulation science and diagnostic technology offer promising tools for prevention and personalization, the current unregulated market allows pseudoscience and marketing exaggeration to flourish unchecked. A more robust, hybrid regulatory model is needed—one that maintains innovation while enforcing minimum safety and efficacy standards. Simultaneously, dermatologists, researchers, and cosmetic chemists must collaborate to educate consumers, advocate for transparency, and ensure that bioactive skincare evolves from speculative marketing into credible science-based therapy. This review analyzes the current state of cosmeceutical development, focusing on bioactive ingredients such as vitamins, botanicals, and antioxidants, while addressing the ethical and scientific concerns associated with unregulated claims. With advances in nanotechnology, diagnostic cosmetology, and noninvasive skin imaging, new opportunities and challenges are reshaping the industry's role in preventive dermatology. We advocate for a hybrid regulatory framework and greater scientific rigor in product development, alongside enhanced consumer education to ensure both efficacy and safety in the cosmeceutical marketplace. National and international health agencies should consider developing a hybrid regulatory model for cosmeceuticals positioned between cosmetics and pharmaceuticals. This would allow for scientific oversight without stifling innovation. Mandatory reporting of active ingredient concentrations, mechanism of action, and basic safety testing should be standard for all bioactive skincare products. Regulatory agencies and industry watchdogs should reinforce policies that penalize unsubstantiated claims. Marketing should be based on validated scientific data, not speculative interpretations or emotional appeals. Products with therapeutic claims (e.g., anti-aging, anti-acne) must include published efficacy data accessible to clinicians and consumers alike.